With a market capitalization of $16,527,941, Titan Pharmaceuticals Inc has a greater market value than only 7.16% of US stocks.
Equity multiplier, or assets relative to shareholders' equity, comes in at 6.75 for Titan Pharmaceuticals Inc; that's greater than it is for 83.59% of US stocks.
Titan Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -118.88%, greater than the shareholder yield of just 3.68% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Titan Pharmaceuticals Inc are ESLT, RNWK, LEDS, NEON, and SPNS.
Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company was founded in 1992 and is based in South San Francisco, California.
Titan Pharmaceuticals (TTNP) slips 4.7% in premarket after announcement of a share purchase agreement with certain accredited institutional investors to purchase ~19.4M shares in a registered direct offering at $0.14/share, with net proceeds of ~$2.5M.The offering is expected to close by September 28....
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a share purchase agreement with certain accredited institutional investors to purchase 19,440,000 shares of its common stock in a registered direct offering at a purchase price of $0.14 per share.
In its special meeting, Titan Pharmaceuticals (TTNP) stockholders' approved the proposal to amend its certificate of incorporation to increase the number of authorized shares of common stock from 125M to 225M.Quick look at the company's common shares outstanding:...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved the proposal to amend Titan's certificate of incorporation to increase the number of authorized shares of common stock from 125 million to 225 million (the "Amendment").
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its partner, Molteni Farmaceutici ("Molteni"), has entered into an exclusive distribution agreement with Accord Healthcare Europe…